Tacrine. A cause of fatal hepatotoxicity?
Tacrine, an acetyl cholinesterase inhibitor used in the treatment of Alzheimer's disease, often causes reversible abnormalities in liver enzymes, but significant hepatotoxicity is uncommon. We describe fatal hepatic failure associated with tacrine administration. A 75-year-old woman with Alzheimer's disease, taking tacrine for 14 months, developed progressive jaundice. Liver function abnormalities developed during tacrine treatment and led to hepatic failure and death. An extensive evaluation for other etiologies of liver disease was negative. Other potentially hepatotoxic medicines had been administered for at least 2 years before beginning tacrine, and postmortem examination of the liver was consistent with drug-induced hepatotoxicity. Approximately half the patients treated with tacrine have liver enzyme abnormalities develop, primarily in the first 12 weeks of therapy, that resolve with discontinuation of drug or dosage adjustment. Our case of tacrine-associated hepatotoxicity 14 months after the initiation of treatment despite regular biochemical evaluation suggests the potential for delayed and fatal hepatotoxicity with tacrine.
Blackard
W G
WG
Department of Medicine, University of Alabama at Birmingham 35294-0007, USA.
Sood
G K
GK
Crowe
D R
DR
Fallon
M B
MB
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D017114:Liver Failure, Acute / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D008111:Liver Function Tests; D018697:Nootropic Agents / Q000009:adverse effects*; D013619:Tacrine / Q000009:adverse effects*
D018697:Nootropic Agents; D013619:Tacrine